A biopharmaceutical company focused on developing treatments for rare diseases, with FDA-approved drugs for conditions like epidermolysis bullosa and pemphigus vulgaris, and two orphan drug designations.
2
Orphan Designations
0 approved
7
FDA Approvals
Latest: KLISYRI (2020)
0
Active Trials
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Almirall, LLC is a company with 2 orphan drug designations across 2 rare diseases, including 7 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acquired epidermolysis bullosa | (S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile | Des.TrialAppr. |
| pemphigus vulgaris | (S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio